ClinicalTrials.gg
TerminatedNCT05126238Updated Sep 25, 2025

A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction

A Phase 3 interventional study of Lithium Carbonate and Placebo in Carotid Artery Diseases and Carotid Artery Stenosis, sponsored by Negovsky Reanimatology Research Institute. Terminated at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Primary conditionCarotid StenosisRegistry: Carotid Artery DiseasesReclassifiedWhy we changed it
Registry
Carotid Artery Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carotid Stenosis
Why
  1. The study's listed conditions name Carotid Stenosis, a narrower term within Carotid Artery Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Negovsky Reanimatology Research Institute · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Decision of the local ethics committee

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

There are 10.3 million cases of stroke registered in the world every year; 63% of them lead to death. According to World Health Organization, stroke is one of the most important risk factors of death and early disability.

Carotid artery surgery is a gold standard of hemodynamically significant carotid artery disease treatment. According to some trials, carotid artery surgery decreases the 2-years mortality.

The most important part of carotid artery surgery is a temporary absence of blood flow in the carotid artery. The duration of this period is a crucial characteristic of this type of surgery. The absence of blood flow leads to brain ischemia which is the risk factor of postoperative neurocognitive disorders such as emergence delirium, postoperative delirium and postoperative cognitive dysfunction.

Some surgical and non-surgical methods for brain protection were evaluated. According to recent data, there is no evidence of effective pharmacological protective methods that can decrease brain damage during carotid artery surgery.

Nevertheless, some trials demonstrated that using lithium-based medications for patients with a stroke can reduce the volume of the stroke. Therefore, the investigators want to check the hypothesis that using lithium-based medication in the preoperative period can reduce brain damage during carotid artery surgery.

The objectives of this trial:

  1. To determine if Lithium carbonate is superior to placebo for the occurrence of emergence delirium, agitation, postoperative delirium and postoperative cognitive dysfunction.
  2. To determine if Lithium carbonate is non-inferior to placebo for the occurrence of a new arrhythmia, leukocytosis, acute kidney injury, seizure disorders, diarrhea, nausea, and vomit.
Read the detailed description

There are 10.3 million cases of stroke registered in the world every year; 63% of them lead to death. According to World Health Organization, stroke is one of the most important risk factors of death and early disability.

Carotid artery surgery is a gold standard of hemodynamically significant carotid artery disease treatment. According to some trials, carotid artery surgery decreases the 2-years mortality.

The most important part of carotid artery surgery is a temporary absence of blood flow in the carotid artery. The duration of this period is a crucial characteristic of this type of surgery. The absence of blood flow leads to brain ischemia which is the risk factor of postoperative neurocognitive disorders such as emergence delirium, postoperative delirium and postoperative cognitive dysfunction.

Some surgical and non-surgical methods for brain protection were evaluated. According to recent data, there is no evidence of effective pharmacological protective methods that can decrease brain damage during carotid artery surgery.

Nevertheless, some trials demonstrated that using lithium-based medications for patients with a stroke can reduce the volume of the stroke. Therefore, the investigators want to check the hypothesis that using lithium-based medication in the preoperative period can reduce brain damage during carotid artery surgery.

The objectives of this trial:

To determine if Lithium carbonate is superior to placebo for the occurrence of emergence delirium, agitation, postoperative delirium and postoperative cognitive dysfunction.

To determine if Lithium carbonate is non-inferior to placebo for the occurrence of a new arrhythmia, leukocytosis, acute kidney injury, seizure disorders, diarrhea, nausea, and vomit.

02

Conditions studied

  • Carotid Artery Diseases
  • Carotid Artery Stenosis

Keywords

  • Carotid artery diseases
  • Carotid artery stenosis
  • Carotid artery surgery
  • Lithium
  • Neurocognitive disorders
  • Postoperative cognitive disorders
  • Postoperative delirium
  • Emergence delirium
  • Agitation
  • Stroke
  • Neuroinflammation
03

In context

Carotid Stenosis Reclassified

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

This study's enrollment of 107 is close to the median of 102 across 192 interventional studies indexed under Carotid Stenosis.

Browse Carotid Stenosis studies →

Lead sponsor

Negovsky Reanimatology Research Institute is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Compared within Carotid Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Carotid Artery Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age > 18 years
  • elective carotid artery surgery
  • general anesthesia
  • written

Exclusion criteria

Exclusion Criteria:

  • urgent surgery
  • recent ( \< 1 month) overt stroke
  • \< 20 points
  • The presence of any mental disorder according to the International Classification of Diseases 11th Revision which is confirmed by a psychiatrist.
  • The presence of any neuromuscular disease according to the International Classification of Diseases 11th Revision
  • or known allergy to lithium carbonate
  • History of seizure disorder
  • History of leukemia
  • Estimated \< 30 ml/min/1.73 m2
  • \< 30%
  • Heart failure equal 3 or 4 class according to the Functional Classification
  • Pregnant or breast-feeding women
  • Inability to undergo a preoperative assessment for any reason
  • Previously enrolled in this trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Lithium

    In preoperative period patients will take 300mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery, they will take 300mg of lithium carbonate 2 hours before surgery. After the surgery, patients will take 300mg of lithium carbonate in the afternoon and 300mg of lithium carbonate in the evening.

    Drug: Lithium Carbonate

  • Placebo comparator
    Placebo

    In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery, they will take placebo 2 hours before surgery. After the surgery, patients will take placebo in the afternoon and in the evening.

    Drug: Placebo

Interventions

  • In preoperative period patients will take 300 mg of lithium carbonate on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will take 300mg of lithium carbonate 2 hours before surgery.

  • DrugPlacebo

    In preoperative period patients will take placebo on 1-1-1 regimen during 2 days prior to surgery. On the day of surgery they will placebo 2 hours before surgery.

06

What researchers measure

Primary outcomes

  1. Frequency of emergence delirium

    Number of patients with positive the confusion assessment method for the intensive care unit as soon as they reach Aldrete score of 9 points

    Time frame: 30 days

Secondary outcomes

  1. Frequency of agitation

    Richmond agitation-sedation scale more or equal +2 evaluated from the end of volatile anesthetic supply to the moment when a patient reaches Aldrete score of 9 points Richmond agitation-sedation scale: minimum value = -5 (Unarousable - no response to voice or physical stimulation) maximum value = +4 (Combative - overtly combative or violent; immediate danger to staff) Adequate patients have the results of Richmond agitation-sedation score equal 0 (Alert and calm; Spontaneously pays attention to caregiver)

    Time frame: 30 days

  2. Frequency of postoperative delirium

    Number of patients with even one positive confusion assessment method for the intensive care unit or 3-minute confusion assessment method

    Time frame: 30 days

  3. Length of postoperative delirium

    30 days - number of days in which patient had positive confusion assessment method for the intensive care unit or 3-minute confusion assessment method

    Time frame: until 1 month after surgery

  4. Frequency of overt strokes

    Number of overt strokes

    Time frame: 1 year

  5. Frequency of covert strokes

    Number of covert strokes

    Time frame: 1 year

  6. Length of stay in intensive care unit

    Number of days in intensive care unit

    Time frame: 1 month

  7. Length of hospitalization

    Number of days in hospital

    Time frame: 1 month

  8. Frequency of cardiac death

    Number of of cardiac deaths

    Time frame: 1 year

  9. Frequency of non-fatal cardiac arrest

    Number of non-fatal cardiac arrests

    Time frame: 1 year

  10. Frequency of major adverse cardiac event

    Number of major adverse cardiac events

    Time frame: 1 year

  11. Frequency of major adverse cardiac and cognitive event

    Number of major adverse cardiac and cognitive events

    Time frame: 1 year

  12. 30-days mortality

    Number of deaths in period of 30 days after surgery

    Time frame: 30 days

  13. 1-year mortality

    Number of deaths in period of 1 year after surgery

    Time frame: 1 year

  14. Frequency of new postoperative arrhythmia

    Number of new postoperative arrhythmias

    Time frame: 1 month

  15. Frequency of leukocytosis

    Number of patients with leukocytosis

    Time frame: From 2 days before surgery to the day of surgery

  16. Frequency of acute diarrhea

    Number of patients with acute diarrhea

    Time frame: From 2 days before surgery to the day of surgery

  17. Frequency of postoperative nausea and vomit

    Number of patients with postoperative nausea and vomit

    Time frame: 1 month

  18. Frequency of preoperative nausea and vomit

    Number of patients with preoperative nausea and vomit

    Time frame: From 2 days before surgery to the day of surgery

  19. Frequency of acute kidney injury

    Number of patients with acute kidney injury

    Time frame: 1 month

  20. Frequency of myasthenia

    Number of patients with myasthenia

    Time frame: From 2 days before surgery to the day of surgery

  21. Frequency of preoperative seizure

    Number of patients with seizure

    Time frame: From 2 days before surgery to the day of surgery

  22. Frequency of postoperative seizure

    Number of patients with seizure

    Time frame: 1 month

  23. Serum level of S100 beta protein

    Serum level of S100 beta protein

    Time frame: 2 days after surgery

  24. Serum level of neuron-specific enolase

    Serum level of neuron-specific enolase

    Time frame: 2 days after surgery

  25. Serum level of Tau-protein

    Serum level of Tau-protein

    Time frame: 2 days after surgery

  26. Serum level of Neurofilament light polypeptide

    Serum level of Neurofilament light polypeptide

    Time frame: 2 days after surgery

  27. Serum level of Glial fibrillary acidic protein

    Serum level of Glial fibrillary acidic protein

    Time frame: 2 days after surgery

07

Study locations

1 site
  • Demikhov Municipal Clinical Hospital 68
    Moscow, Russia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in May 2025, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2021
First posted
Nov 18, 2021
StartActual
Nov 20, 2021
Primary completionActual
May 19, 2025
CompletionActual
May 19, 2025
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05126238
Lead sponsor
Negovsky Reanimatology Research Institute
Collaborators
Demikhov Municipal Clinical Hospital 68
Responsible party
Valery Likhvantsev, MD (Head of the Research V. Negovsky Reanimatology Research Institute, Negovsky Reanimatology Research Institute) — Principal investigator
First posted
Nov 18, 2021
Start date
Nov 20, 2021
Primary completion
May 19, 2025
Completion
May 19, 2025
Last update
Sep 25, 2025

Study contacts

Valery Likhvantsev, PhD
principal investigator · Negovsky Reanimatology Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lithium Carbonate

Start the discussion